From Molecules to Minds: Redefining the Power of Psychedelics and Entactogens in Treating Brain Disorders
CNS & Neurological Disorders - Drug Targets July 31, 2026 Sampriti Paul, Sonal Dubey, Mayur Yergeri Chandrasekharappa et al.
Recent advances in neuropsychopharmacology have renewed interest in psychedelics and entactogens as potential treatments for brain disorders, owing to their rapid effects on neural plasticity, cognition, and affect. Classical serotonergic psychedelics primarily act as 5-HT2A receptor agonists with additional activity at 5-HT1A and other serotonin receptors, whereas entactogens such as MDMA...